Status:

COMPLETED

Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis (MARC)

Lead Sponsor:

University Hospital, Clermont-Ferrand

Conditions:

End Stage Renal Disease

Eligibility:

All Genders

18+ years

Brief Summary

The primary purpose of this study is to validate a mathematical modeling of treatment by intermittent hemodialysis using regional citrate anticoagulation with a dialysate containing calcium

Detailed Description

The only visit to the study will be carried out during a usual dialysis session in the intensive care unit of Clermont-Ferrand University Hospital. In addition to the usual care, 2 blood samples will ...

Eligibility Criteria

Inclusion

  • Major patient;
  • Man or woman ;
  • Treated with intermittent hemodialysis for chronic renal failure;
  • In whom intermittent hemodialysis with citrate solution for regional anticoagulation is indicated;
  • Affiliated with a social security scheme;
  • Having given a signed agreement after detailed explanation of the protocol on the basis of the information sheet and likely to comply with it

Exclusion

  • Severe hepato-cellular insufficiency (PT \<50%, INR\> 1.5 without anticoagulant);
  • Hemoglobin level \<7 g / dL
  • Presenting a psychiatric pathology or cognitive impairment rendering him unable to give informed consent;
  • Persons under guardianship, curatorship, deprived of liberty or safeguard of justice
  • Pregnant or breastfeeding women
  • Patient's refusal to participate in the study.

Key Trial Info

Start Date :

February 2 2021

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 7 2021

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04530175

Start Date

February 2 2021

End Date

July 7 2021

Last Update

February 9 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHU de Clermont-Ferrand

Clermont-Ferrand, France, 63000